NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT1040200050

Registered date:08/10/2020

Circulating biomarkers in hormone-producing tumors

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedhormone producing endocrine tumor
Date of first enrollment08/10/2020
Target sample size420
Countries of recruitment
Study typeObservational
Intervention(s)

Outcome(s)

Primary Outcomechanges in the candidate circulating biomarker that is newly detected in this study after the treatment of its hormone-producing endocrine tumor
Secondary Outcomecorrelation between the levels of the candidate circulating biomarker and the parameters of the physical exam or biochemistry

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
GenderBoth
Include criteriaSelection criteria 1) From April 1, 2002 to December 31, 2023, a hormone-producing endocrine tumor that was diagnosed by functional tests and imaging tests at our hospital, endocrinology / metabolism internal medicine, former first internal medicine, and former second internal medicine. In addition, patients with abnormal metabolism (obesity, hypertension, abnormal glucose metabolism, cardiovascular disease, non-alcoholic fatty liver disease) who are not diagnosed as hormone production, and patients with non-hormone-producing endocrine tumors. Each diagnostic criterion follows each guideline and consensus statement. 2) Being over 20 years old and able to go to the hospital. 3) The functions of major organs (below) are retained by clinical examination within 30 days before registration. 1 White blood cell : 3,000 <= WBC <15,000 / mcL 2 Hemoglobin: Hb >= 10.0 g / dL 3 Platelet count: Platelet >= 50,000 / mcL 4 Total bilirubin: T.Bil <= 2.0 mg / dL 5 Serum creatinine: Cr <= 2.5 mg / dL 4) Patients who have received sufficient explanation before participating in this study, and who have obtained sufficient understanding and voluntary written consent of the patient.
Exclude criteriaExclusion criteria 1) using oral or intravenous steroids. 2) serious infection, before or after surgery, or if you have serious trauma. 3) malignant tumor (including a history). 4) the principal investigator or the investigator judges that it is inappropriate as the subject of this research.

Related Information

Contact

Public contact
Name Yujiro Nakano
Address 13-1 Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan Ishikawa Japan 920-8641
Telephone +81-76-265-2711
E-mail yujironakano@staff.kanazawa-u.ac.jp
Affiliation Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Scientific contact
Name Toshinari Takamura
Address 13-1 Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan Ishikawa Japan 920-8641
Telephone +81-76-265-2711
E-mail ttakamura@med.kanazawa-u.ac.jp
Affiliation Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.